​

Intellia Therapeutics (NTLA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

NTLA Stock Forecast

Intellia Therapeutics stock forecast is as follows: an average price target of $53.00 (represents a 338.74% upside from NTLA’s last price of $12.08) and a rating consensus of 'Buy', based on 14 wall street analysts offering a 1-year stock forecast.

NTLA Price Target

The average price target for Intellia Therapeutics (NTLA) is $53.00 based on 1-year price targets from 14 Wall Street analysts in the past 3 months, with a price target range of $80.00 to $18.00. This represents a potential 338.74% upside from NTLA's last price of $12.08.

NTLA Analyst Ratings

Buy

According to 14 Wall Street analysts, Intellia Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for NTLA stock is 0 'Strong Buy' (0.00%), 14 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Intellia Therapeutics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 11, 2024Jay OlsonOppenheimer$60.00$17.16249.65%396.69%
Oct 24, 2024Jack AllenRobert W. Baird$18.00$15.8513.56%49.01%
Aug 09, 2024Luca IssiRBC Capital$54.00$22.38141.29%347.02%
Jun 24, 2024Dae Gon HaStifel Nicolaus$80.00$25.22217.21%562.25%
Jun 24, 2024Jack AllenRobert W. Baird$24.00$26.00-7.67%98.68%
May 10, 2024Kostas BiliourisBMO Capital$70.00$24.84181.80%479.47%
Feb 01, 2023Cantor Fitzgerald$67.00$42.4457.87%454.64%
Jan 04, 2023Wells Fargo$120.00$36.64227.51%893.38%
Dec 06, 2022Credit Suisse$88.00$40.03119.84%628.48%
Dec 02, 2022Leerink Partners$86.00$45.8087.77%611.92%
Nov 15, 2022Chardan Capital$129.00$53.30142.03%967.88%
Aug 05, 2022Leerink Partners$152.00$61.98145.24%1158.28%
Aug 05, 2022Chardan Capital$146.00$61.28138.25%1108.61%
Jun 16, 2022Kostas BiliourisBMO Capital$54.00$41.4430.31%347.02%
May 09, 2022JMP Securities$110.00$47.57131.24%810.60%
May 09, 2022Steven SeedhouseRaymond James$105.00$47.57120.73%769.21%
May 06, 2022Credit Suisse$98.00$46.20112.12%711.26%
Feb 24, 2022Luca IssiRBC Capital$150.00$87.4671.51%1141.72%
Feb 18, 2022Raju PrasadWilliam Blair$144.00$86.5266.44%1092.05%
Feb 15, 2022Joon LeeTruist Financial$160.00$98.5262.40%1224.50%
Feb 03, 2022Swapnil MalekarPiper Sandler$171.00$94.5380.89%1315.56%
Feb 03, 2022David NierengartenWedbush$108.00$94.5314.25%794.04%
Nov 16, 2021Anthony ButlerRoth Capital$180.00$137.5130.90%1390.07%
Aug 06, 2021Steven SeedhouseRaymond James$181.00$167.318.18%1398.34%
Aug 06, 2021Salveen RichterGoldman Sachs$252.00$167.3150.62%1986.09%
Aug 05, 2021Gena WangBarclays$207.00$165.1625.33%1613.58%
Jun 22, 2021Maury RaycroftJefferies$109.00$78.9138.13%802.32%

The latest Intellia Therapeutics stock forecast, released on Nov 11, 2024 by Jay Olson from Oppenheimer, set a price target of $60.00, which represents a 249.65% increase from the stock price at the time of the forecast ($17.16), and a 396.69% increase from NTLA last price ($12.08).

Intellia Therapeutics Price Target by Period

1M3M12M
# Anlaysts-26
Avg Price Target-$39.00$51.00
Last Closing Price$12.08$12.08$12.08
Upside/Downside-100.00%222.85%322.19%

In the current month, the average price target of Intellia Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Intellia Therapeutics's last price of $12.08. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 11, 2024OppenheimerOutperformOutperformHold
Oct 16, 2024BMO CapitalOutperformOutperformHold
Sep 11, 2024RBC CapitalBuyBuyHold
Aug 12, 2024RBC CapitalBuyBuyHold
Aug 12, 2024Cantor FitzgeraldUnderperformUnderperformHold
Aug 09, 2024RBC CapitalOutperformOutperformHold
Jun 26, 2024BMO CapitalOutperformOutperformHold
Jun 24, 2024WedbushBuyBuyHold
Jun 04, 2024WedbushNeutralNeutralHold
Jun 04, 2024CitigroupUnderperformUnderperformHold
Jun 03, 2024Cowen & Co.BuyBuyHold
Jun 03, 2024CitigroupNeutralNeutralHold
May 10, 2024BMO CapitalOutperformOutperformHold
May 10, 2024CitigroupNeutralNeutralHold
Aug 07, 2023BarclaysOverweightOverweightHold
Mar 14, 2023JonesTradingBuyInitialise
Mar 13, 2023BMO CapitalMarket PerformOutperformUpgrade
Feb 01, 2023Cantor FitzgeraldOverweightInitialise
Jan 04, 2023Wells FargoOverweightOverweightHold
Dec 06, 2022Credit SuisseOutperformOutperformHold
Dec 02, 2022SVB LeerinkOutperformOutperformHold
Nov 15, 2022Chardan CapitalBuyBuyHold
Sep 19, 2022SVB LeerinkOutperformOutperformHold
Aug 05, 2022SVB LeerinkOutperformOutperformHold
Aug 05, 2022Chardan CapitalBuyBuyHold
Jun 17, 2022BMO CapitalMarket PerformInitialise
May 24, 2022Goldman SachsBuyBuyHold
May 09, 2022Raymond JamesBuyBuyHold
Feb 18, 2022William BlairOutperformInitialise

Intellia Therapeutics's last stock rating was published by Oppenheimer on Nov 11, 2024. The company gave NTLA a "Outperform" rating, the same as its previous rate.

Intellia Therapeutics Financial Forecast

Intellia Therapeutics Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue-------------$11.99M$13.59M$12.61M$13.57M$13.27M$14.03M$11.25M$12.85M$7.20M$6.55M$6.45M$6.59M$22.22M$16.26M$12.92M$10.94M$10.62M
Avg Forecast$10.10M$9.99M$9.87M$9.76M$9.72M$9.54M$11.99M$9.36M$9.29M$8.28M$19.68M$11.24M$12.74M$13.05M$12.08M$11.83M$11.33M$11.89M$9.42M$8.54M$8.26M$8.66M$12.21M$9.86M$13.14M$14.90M$9.53M$21.98M$9.58M$9.17M
High Forecast$16.47M$16.29M$16.10M$15.92M$15.85M$15.56M$19.56M$15.25M$26.93M$13.50M$19.68M$11.24M$35.29M$13.35M$19.69M$19.29M$18.48M$11.89M$9.42M$8.54M$8.26M$8.66M$12.21M$9.86M$13.14M$14.90M$9.53M$21.98M$9.58M$9.17M
Low Forecast$5.49M$5.43M$5.37M$5.31M$5.28M$5.19M$6.52M$5.08M$3.10M$4.50M$19.68M$11.24M$4.81M$12.75M$6.56M$6.43M$6.16M$11.89M$9.42M$8.54M$8.26M$8.66M$12.21M$9.86M$13.14M$14.90M$9.53M$21.98M$9.58M$9.17M
# Analysts3345452715799102010109999101010101087655
Surprise %-------------0.92%1.13%1.07%1.20%1.12%1.49%1.32%1.56%0.83%0.54%0.65%0.50%1.49%1.71%0.59%1.14%1.16%

Intellia Therapeutics's average Quarter revenue forecast for Dec 23 based on 10 analysts is $12.74M, with a low forecast of $4.81M, and a high forecast of $35.29M. NTLA's average Quarter revenue forecast represents a 6.28% increase compared to the company's last Quarter revenue of $11.99M (Sep 23).

Intellia Therapeutics EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts3345452715799102010109999101010101087655
EBITDA-------------$-122.22M$-123.68M$-111.86M$-104.66M$-95.77M$-98.47M$-142.07M$-79.36M$-69.86M$-67.17M$-44.61M$-40.59M$-26.24M$-30.83M$-30.27M$-26.69M$-22.25M
Avg Forecast$-10.10M$-9.99M$-9.87M$-9.76M$-9.72M$-9.54M$-11.99M$-9.36M$-9.29M$-8.28M$-19.68M$-133.90M$-12.74M$-13.05M$-12.08M$-121.73M$-73.36M$-11.89M$-9.42M$-110.66M$-8.26M$-8.66M$-12.21M$-42.59M$-13.14M$-14.90M$-9.53M$-16.65M$-9.58M$-9.17M
High Forecast$-5.49M$-5.43M$-5.37M$-5.31M$-5.28M$-5.19M$-6.52M$-5.08M$-3.10M$-4.50M$-19.68M$-107.12M$-4.81M$-12.75M$-6.56M$-97.38M$-58.69M$-11.89M$-9.42M$-88.53M$-8.26M$-8.66M$-12.21M$-34.07M$-13.14M$-14.90M$-9.53M$-13.32M$-9.58M$-9.17M
Low Forecast$-16.47M$-16.29M$-16.10M$-15.92M$-15.85M$-15.56M$-19.56M$-15.25M$-26.93M$-13.50M$-19.68M$-160.69M$-35.29M$-13.35M$-19.69M$-146.08M$-88.04M$-11.89M$-9.42M$-132.80M$-8.26M$-8.66M$-12.21M$-51.10M$-13.14M$-14.90M$-9.53M$-19.97M$-9.58M$-9.17M
Surprise %-------------9.37%10.24%0.92%1.43%8.06%10.46%1.28%9.60%8.07%5.50%1.05%3.09%1.76%3.23%1.82%2.79%2.43%

undefined analysts predict NTLA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Intellia Therapeutics's previous annual EBITDA (undefined) of $NaN.

Intellia Therapeutics Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts3345452715799102010109999101010101087655
Net Income-------------$-122.22M$-123.68M$-92.34M$-116.73M$-111.28M$-99.97M$-149.50M$-81.24M$-71.64M$-68.81M$-46.20M$-42.19M$-27.84M$-32.39M$-31.81M$-28.28M$-23.63M
Avg Forecast$-116.52M$-118.27M$-121.08M$-135.49M$-141.86M$-143.02M$-138.23M$-138.81M$-135.23M$-140.41M$-122.90M$-136.03M$-145.29M$-151.35M$-133.41M$-123.66M$-75.10M$-124.65M$-126.45M$-112.42M$-92.03M$-82.14M$-61.50M$-44.10M$-58.43M$-57.30M$-67.02M$-17.49M$-54.58M$-60.03M
High Forecast$-47.37M$-48.08M$-49.22M$-55.08M$-57.67M$-58.14M$-56.19M$-114.67M$-88.15M$-57.08M$-49.96M$-108.82M$-99.82M$-122.09M$-54.24M$-98.93M$-60.08M$-124.65M$-126.45M$-89.94M$-92.03M$-82.14M$-61.50M$-35.28M$-58.43M$-57.30M$-67.02M$-13.99M$-54.58M$-60.03M
Low Forecast$-212.01M$-215.20M$-220.31M$-246.53M$-258.11M$-260.23M$-251.52M$-152.90M$-161.27M$-255.48M$-223.63M$-163.23M$-164.06M$-179.60M$-242.75M$-148.40M$-90.12M$-124.65M$-126.45M$-134.90M$-92.03M$-82.14M$-61.50M$-52.93M$-58.43M$-57.30M$-67.02M$-20.99M$-54.58M$-60.03M
Surprise %-------------0.81%0.93%0.75%1.55%0.89%0.79%1.33%0.88%0.87%1.12%1.05%0.72%0.49%0.48%1.82%0.52%0.39%

Intellia Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. NTLA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Intellia Therapeutics SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts3345452715799102010109999101010101087655
SG&A-------------$29.40M$30.65M$27.45M$23.63M$22.14M$22.13M$22.40M$22.11M$18.71M$16.68M$13.59M$10.76M$10.57M$11.53M$11.31M$8.98M$8.43M
Avg Forecast$17.80M$17.60M$17.40M$17.20M$17.12M$16.81M$21.13M$16.48M$16.36M$14.59M$34.67M$19.81M$22.45M$22.99M$21.28M$20.85M$19.97M$20.94M$16.59M$15.05M$14.56M$15.26M$21.52M$17.37M$23.16M$26.26M$16.79M$6.22M$16.88M$16.15M
High Forecast$29.03M$28.69M$28.37M$28.04M$27.92M$27.41M$34.46M$26.88M$47.45M$23.79M$34.67M$19.81M$62.17M$23.52M$34.70M$33.99M$32.56M$20.94M$16.59M$15.05M$14.56M$15.26M$21.52M$17.37M$23.16M$26.26M$16.79M$7.47M$16.88M$16.15M
Low Forecast$9.68M$9.56M$9.46M$9.35M$9.31M$9.14M$11.49M$8.96M$5.45M$7.93M$34.67M$19.81M$8.48M$22.46M$11.57M$11.33M$10.85M$20.94M$16.59M$15.05M$14.56M$15.26M$21.52M$17.37M$23.16M$26.26M$16.79M$4.98M$16.88M$16.15M
Surprise %-------------1.28%1.44%1.32%1.18%1.06%1.33%1.49%1.52%1.23%0.78%0.78%0.46%0.40%0.69%1.82%0.53%0.52%

Intellia Therapeutics's average Quarter SG&A projection for Dec 23 is $22.45M, based on 10 Wall Street analysts, with a range of $8.48M to $62.17M. The forecast indicates a -23.63% fall compared to NTLA last annual SG&A of $29.40M (Sep 23).

Intellia Therapeutics EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts3345452715799102010109999101010101087655
EPS-------------$-1.38$-1.40$-1.05$-1.44$-1.46$-1.32$-2.00$-1.09$-0.97$-1.01$-0.69$-0.69$-0.47$-0.61$-0.63$-0.60$-0.49
Avg Forecast$-1.15$-1.17$-1.20$-1.34$-1.40$-1.42$-1.37$-1.37$-1.34$-1.39$-1.22$-1.37$-1.44$-1.50$-1.32$-1.40$-1.38$-1.29$-1.30$-1.11$-0.95$-0.85$-0.63$-0.66$-0.60$-0.59$-0.69$-0.43$-0.56$-0.62
High Forecast$-0.47$-0.48$-0.49$-0.55$-0.57$-0.58$-0.56$-1.14$-0.87$-0.57$-0.49$-0.56$-0.99$-1.21$-0.54$-0.57$-0.56$-1.29$-1.30$-1.11$-0.95$-0.85$-0.63$-0.66$-0.60$-0.59$-0.69$-0.43$-0.56$-0.62
Low Forecast$-2.10$-2.13$-2.18$-2.44$-2.56$-2.58$-2.49$-1.51$-1.60$-2.53$-2.21$-2.49$-1.62$-1.78$-2.40$-2.55$-2.51$-1.29$-1.30$-1.11$-0.95$-0.85$-0.63$-0.66$-0.60$-0.59$-0.69$-0.43$-0.56$-0.62
Surprise %-------------0.92%1.06%0.75%1.04%1.14%1.01%1.80%1.15%1.15%1.59%1.05%1.15%0.80%0.88%1.46%1.07%0.79%

According to undefined Wall Street analysts, Intellia Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to NTLA previous annual EPS of $NaN (undefined).

Intellia Therapeutics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
EDITEditas Medicine$1.52$10.20571.05%Buy
PRMEPrime Medicine$2.91$17.25492.78%Buy
SANASana Bio$1.91$8.00318.85%Buy
NTLAIntellia Therapeutics$13.13$53.00303.66%Buy
FATEFate Therapeutics$1.88$5.00165.96%Buy
VERVVerve Therapeutics$5.61$14.00149.55%Buy
BEAMBeam Therapeutics$28.58$55.0092.44%Buy
CRSPCRISPR Therapeutics$44.63$77.5073.65%Buy
CRBUCaribou Biosciences$1.94$3.0054.64%Buy
VRTXVertex Pharmaceuticals$469.24$533.3013.65%Buy
DNAGinkgo Bioworks$9.61$7.00-27.16%Buy

NTLA Forecast FAQ

Is Intellia Therapeutics a good buy?

Yes, according to 14 Wall Street analysts, Intellia Therapeutics (NTLA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 14 'Buy' recommendations, accounting for 100.00% of NTLA's total ratings.

What is NTLA's price target?

Intellia Therapeutics (NTLA) average price target is $53 with a range of $18 to $80, implying a 338.74% from its last price of $12.08. The data is based on 14 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Intellia Therapeutics stock go up soon?

According to Wall Street analysts' prediction for NTLA stock, the company can go up by 338.74% (from the last price of $12.08 to the average price target of $53), up by 562.25% based on the highest stock price target, and up by 49.01% based on the lowest stock price target.

Can Intellia Therapeutics stock reach $20?

NTLA's average twelve months analyst stock price target of $53 supports the claim that Intellia Therapeutics can reach $20 in the near future.

What are Intellia Therapeutics's analysts' financial forecasts?

Intellia Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $40.61M (high $66.22M, low $22.07M), average EBITDA is $-40.613M (high $-22.073M, low $-66.218M), average net income is $-562M (high $-287M, low $-923M), average SG&A $71.55M (high $116.67M, low $38.89M), and average EPS is $-5.563 (high $-2.838, low $-9.136). NTLA's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $39.73M (high $64.78M, low $21.59M), average EBITDA is $-39.73M (high $-21.592M, low $-64.777M), average net income is $-491M (high $-200M, low $-894M), average SG&A $70M (high $114.13M, low $38.04M), and average EPS is $-4.865 (high $-1.978, low $-8.852).

Did the NTLA's actual financial results beat the analysts' financial forecasts?

Based on Intellia Therapeutics's last annual report (Dec 2022), the company's revenue was $52.12M, beating the average analysts forecast of $41.18M by 26.58%. Apple's EBITDA was $-445M, beating the average prediction of $-205M by 116.57%. The company's net income was $-490M, beating the average estimation of $-439M by 11.76%. Apple's SG&A was $90.31M, beating the average forecast of $72.55M by 24.48%. Lastly, the company's EPS was $-6.37, beating the average prediction of $-5.077 by 25.47%. In terms of the last quarterly report (Sep 2023), Intellia Therapeutics's revenue was $11.99M, missing the average analysts' forecast of $13.05M by -8.10%. The company's EBITDA was $-122M, beating the average prediction of $-13.048M by 836.69%. Intellia Therapeutics's net income was $-122M, missing the average estimation of $-151M by -19.24%. The company's SG&A was $29.4M, beating the average forecast of $22.99M by 27.90%. Lastly, the company's EPS was $-1.38, missing the average prediction of $-1.498 by -7.91%